Oxurion NV (XBRU:OXUR) Institutional Ownership : 0.00% (As of Apr. 28, 2024)

View and export this data going back to 2006. Start your Free Trial

What is Oxurion NV Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Oxurion NV's institutional ownership is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Oxurion NV's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Oxurion NV's Float Percentage Of Total Shares Outstanding is 0.00%.

Oxurion NV Institutional Ownership Historical Data

The historical data trend for Oxurion NV's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxurion NV Institutional Ownership Chart

Oxurion NV Historical Data

The historical data trend for Oxurion NV can be seen below:

	2022-08-31	2022-09-30	2022-10-31	2022-11-30	2022-12-31	2023-01-31	2023-02-28	2023-03-31	2023-04-30	2023-05-31
Institutional Ownership	6.03	5.77	4.44	1.52	1.07	0.79	0.54	0.01	0.01	0.01

Oxurion NV Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Oxurion NV (XBRU:OXUR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxurion NV (XBRU:OXUR) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

TG4:Germany

Address

Gaston Geenslaan 1, Leuven, BEL, B-3001

Website

https://www.oxurion.com

Oxurion NV is a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME). The Group's research and development facilities are located in Belgium .The Company is engaged in the development of drugs to treat back-of-the-eye diseases, more specifically, ophthalmologic pharmaceuticals to treat vascular retinal disorders, specifically DME.

Oxurion NV (XBRU:OXUR) Headlines

No Headlines